bpc-157 safety adverse effects case reports An FDA advisory panel narrowly voted to ease restrictions on injectable “wellness” peptides like and TB-500, despite FDA scientists warning there's little evidence they're safe or effective. If the FDA follows Multifunctionality and Possible Medical Application

Inject subcutaneously or intramuscularly (may be injected intravenously at the discretion of the veterinarian) Multi-species label

Neither compound is FDA-approved as a drug

Subcutaneous injections can be done by the patient themselves

Flags theoretical pathologic angiogenesis potential: PMC12446177 Evidence Summary Preclinical: IBD/colitis models: High remission rates, restored mucosal architecture, improved barrier function Tendon repair: Accelerated healing, improved tensile strength, reduced fibrosis Neurovascular: Sciatic nerve protection, enhanced blood vessel growth in nerve tissue Human data (emerging): Interstitial cystitis pilot (2024, n=12): 10/12 complete resolution, 2/12 at 80% improvement IV safety study (2025, n=2): no adverse effects on cardiac, hepatic, renal, or glucose biomarkers Knee pain retrospective (2021, n=17): 91.6% reported significant improvement No large-scale controlled trials published Safety: No immunosuppression or hormonal disruption in available data 2025 systematic review (HSS Journal): recommends caution due to limited high-quality clinical evidence 2025 narrative review: flags theoretical pathologic angiogenesis risk Stable in gastric acid (oral administration viable) No observed toxicity at therapeutic doses in published reports Foundational Reviews Sikiric P, Seiwerth S, et al

PMCID: PMC6770181